



Marie Yeager
Cancer Center

2022

Cancer Care Report

Data collected in 2021 and reported in 2022

Each year we look at cancer cases locally and nationally in order to understand trends, support cancer research, measure progress in prevention efforts, and to improve cancer outcomes.

Spectrum Health Lakeland is accredited with commendation by the Commission on Cancer (CoC) of the American College of Surgeons (ACoS) as a Community Hospital Comprehensive Cancer Program. The Radiation Oncology Department is accredited by the American College of Radiology (ACR). We are fully accredited by the National Accreditation Program for Breast Centers (NAPBC), a program administered by the American College of Surgeons, the College of American Pathologists, and Laboratory Accreditation Certified.

Spectrum Health Lakeland is a member of the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO), and has received the gold seal of approval from The Joint Commission. Understanding the importance of research and participation in trials, we participate in the Michigan Radiation Oncology Quality Consortium and the Cancer Research Consortium of West Michigan.

As an accredited organization we have proven ourselves through legitimate third parties that we meet or exceed strict quality standards.

Read on to learn more about cancer cases from 2021 in Michigan, the United States, and at Lakeland specifically.



spectrumhealthlakeland.org/cancer-care

Statistical summary and review of registry data 2021

In 2021, 1,193 cases were added to the Spectrum Health Lakeland Cancer Registry. Of these cases, 1,085 cases were considered analytic, which means that they received all or part of their first course treatment at Lakeland, or were diagnosed at Lakeland and received all first course treatment elsewhere. The number of cisgender male patients was **537 (45.01%)**, cisgender female patients was **654 (54.82%)**, transgender- assigned female at birth patients was **one (0.8%)**, and transgender- assigned male at birth patients was **one (0.8%)**.

Patients diagnosed at age 60 years or older accounted for 72.17% of cases. Patients 30 through 59 years of age accounted for 25.98%, while 1.84% of cases were 29 years old or younger. The mean age of cancer patients in 2021 was 65.

Non-analytic cases are those that were diagnosed and received all first course treatment elsewhere, and came to Lakeland for subsequent treatment for either recurrence or persistence of their disease.

Figure 1a
2021 ratio of female to male patients




Figure 1b
2021 age distribution




Figure 2
Percent distribution of Lakeland hospitals' 2021 cancer cases by age decade




Table 1

Site distribution by stage for the five most common cancer sites at Lakeland hospitals*

	Cases	Stage 0	Stage I	Stage II	Stage III	Stage IV	UNK Staged
Breast	191	24	107	26	21	11	2
Lung	162	0	51	13	29	67	4
Prostate	139	0	25	50	24	36	4
Colorectal	83	0	18	17	27	18	3
Non-Hodgkins Lymphoma	47	22	15	2	9	15	3

Table 2

Comparison of five most common cancer sites, Lakeland hospitals, state of Michigan, and United States

Site	Lakeland Hospitals			Michigan		United States	
	Rank	Cases	% of Total	Rank	% of Total	Rank	% of Total
Breast	1	191	16.01%	2	14.20%	1	15.40%
Lung	2	162	13.57%	3	13.10%	2	12.60%
Prostate	3	139	11.65%	1	11%	3	10.6
Colon/rectum	4	83	6.95%	4	7.40%	4	8.10%
Non-Hodgkins Lymphoma	5	47	3.90%	7*	4.60%	6*	4.50%

*American Cancer Society. Cancer Facts & Figures 2021. Atlanta: American Cancer Society; 2021, pg 4-5.

Table 3

Comparison of percent distribution of Lakeland hospitals' 2021 cancer cases and United States data by gender and Lakeland's five most common cancer sites

Site	Male Cancer Cases: 537		Female Cancer Cases: 654	
	United States*	Lakeland	United States*	Lakeland
Breast	0.27%	0.18%	30.34%	29.05%
Prostate	25.61%	25.88%	NA	NA
Lung	12.27%	15.00%	12.57%	13%
Colorectal	8.19%	9.00%	7.54%	5.00%
Non-Hodgkins Lymphoma	4.70%	6.00%	3.87%	2.00%

*American Cancer Society. Cancer Facts & Figures 2021. Atlanta: American Cancer Society; 2021 pg 4.

Figure 3
Comparison of percent distributions of Spectrum Health Lakeland’s three most common female and male cancer sites for 2021 and United States data*




Figure 4
Comparison of percent distribution of Lakeland hospitals’ 2021 cancer cases by gender




Figure 5a
Distribution of Lakeland cancer cases by county




Figure 5b
Distribution of Lakeland cancer cases by city
(Berrien, Cass, Van Buren counties)





Figure 6

Distribution of total cancer cases by primary site



*CIN III (non-invasive cervical severe dysplasia) is accessioned by agreement, but for 2021 the collection of this data was mandated by the State of Michigan

Table 4

Summary: By body, system, and gender

Primary Site	Total	Percent	Male	Percent	Female	Percent
BRAIN & OTHER NERVOUS SYSTEM	99	8.3%	23	4.3%	76	11.6%
Brain	10	0.8%	6	1.1%	4	0.6%
Cranial Nerves other Nervous System	89	7.5%	17	3.2%	72	11%
BONES & JOINTS	1	0.1%	0	0%	1	0.2%
BREAST	191	16%	1	0.2%	190	29%
DIGESTIVE SYSTEM	166	13.9%	96	17.9%	69	10.5%
Anus, Anal Canal & Anorectum	10	0.8%	6	1.1%	4	0.6%
Colon Excluding Rectum	64	5.4%	33	6.1%	30	4.6%
Esophagus	13	1.1%	11	2%	2	0.3%
Gallbladder	5	0.4%	1	0.2%	4	0.6%
Liver & Intrahepatic Bile Duct	12	1%	8	1.5%	4	0.6%
Rectum & Rectosigmoid	19	1.6%	15	2.8%	4	0.6%
Small Intestine	4	0.3%	2	0.4%	2	0.3%
Stomach	16	1.3%	10	1.9%	6	0.9%
Other Biliary	1	0.1%	1	0.2%	0	0
PANCREAS	21	1.8%	9	1.7%	12	1.8%
Peritoneum, Omentum & Mesenter	1	0.1	0	0	1	0.2
ENDOCRINE SYSTEM	43	3.6%	16	3%	27	4.1%
Thyroid	13	1.1%	3	0.6%	10	1.5%
Other Endocrine including Thymus	30	2.5%	13	2.4%	17	2.6%
EYE & ORBIT	1	0.1%	1	0.2%	0	0
FEMALE GENITAL SYSTEM	105	8.8%	0	0	105	16%
Cervix Uteri	50	4.2%	0	0	50	7.6%
Corpus & Uterus, NOS	43	3.6%	0	0	43	6.6%
Ovary	4	0.3%	0	0	4	0.6%
Vagina	2	0.2%	0	0	2	0.3%
Vulva	5	0.4%	0	0	5	0.8%
Other Female Genital Organs	1	0.1%	0	0	1	0.2%
LEUKEMIA	40	3.4%	24	4.5%	16	2.4%
Lymphocytic Leukemia	23	1.9%	14	2.6%	9	1.4%
Myeloid & Monocytic Leukemia	14	1.20%	7	1.3%	7	1.1%
Other Leukemia	3	0.3%	3	0.6%	0	0

Table 4 (continued)
Summary: By body, system, and gender

Primary Site	Total	Percent	Male	Percent	Female	Percent
LYMPHOMA	49	4.1%	33	6.1%	16	2.4%
Hodgkins Lymphoma	2	0.2%	1	0.2%	1	0.2%
Non-Hodgkin Lymphoma	47	3.90%	32	6%	15	2.3%
MALE GENITAL SYSTEM	144	12.1%	144	28.8%	0	0
Penis	1	0.1%	1	0.2%	0	0
Prostate	139	11.7%	139	25.9%	0	0
Testis	4	0.3%	4	0.7%	0	0
MESOTHELIOMA	2	0.2%	2	0.4%	0	0
MYELOMA	24	2%	14	2.6%	10	1.5%
ORAL CAVITY & PHARYNX	22	1.8%	11	2%	11	1.7%
Gum and Other Mouth	4	0.3%	1	0.2%	3	0.5%
Hypopharynx	1	0.1%	1	0.2%	0	0
Nasopharynx	1	0.1%	1	0.2%	0	0
Oropharynx	1	0.1%	0	0	1	0.2%
Salivary Glands	3	0.3%	0	0	3	0.5%
Tongue	7	0.6%	5	0.9%	2	0.3%
Tonsil	5	0.4%	3	0.6%	2	0.3%
RESPIRATORY SYSTEM	173	14.5%	89	16.6%	84	12.8%
Larynx	11	0.9%	10	1.9%	1	0.2%
Lung & Bronchus	162	13.6%	79	14.7%	83	12.7%
SKIN EXCLUDING BASAL & SQUAMOUS	32	2.7%	13	2.4	19%	2.9%
Melanoma - Skin	30	2.5%	12	2.2%	18	2.7%
Other Non=Epithelial Skin	2	0.2%	1	0.2%	1	0.2%
SOFT TISSUE (including heart)	6	0.5%	6	1.1%	0	0
URINARY SYSTEM	79	6.6%	55	10.2%	24	3.8%
Kidney & Renal Pelvis	38	3.2%	20	3.7%	18	2.9%
Urinary Bladder	37	3.1%	32	6%	5	0.8%
Ureter	4	0.3%	3	0.6%	1	0.2%
MISCELLANEOUS	16	1.3%	9	1.7%	6	0.9%
Total	1193		537		654	